Form 4: Bioxytran Officer Acquires and Disposes of Shares in Transaction Related to NDPD Pharma Sale
SEC Form 4 Filing
Michael Sheikh, Chief Communications Officer of Bioxytran, reports acquiring and disposing of preferred shares in a transaction related to the sale of NDPD Pharma.
Summary
- Michael Sheikh, Chief Communications Officer of Bioxytran, Inc., filed a Form 4 detailing changes in beneficial ownership.
- The report indicates a transaction on October 24, 2024, where Sheikh acquired 6,473,921 preferred shares at a price of $0.545 per share.
- Following this, Sheikh disposed of 8,073,921 shares.
- The shares were issued as payment for the sale of NDPD Pharma to Bioxytran.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a transaction related to the sale of NDPD Pharma. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's securities, ensuring transparency and compliance with SEC regulations.
Key Dates
| Date | Description |
|---|---|
| 10/24/2024 | Date of transaction: Acquisition and disposition of preferred shares. |
| 10/25/2024 | Date of Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Bioxytran, BIXT, Michael Sheikh, NDPD Pharma, Preferred Shares, Acquisition, Disposition, Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.